MIAMI--(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE: OPK), today announced the presentation of late-breaking clinical data in a poster at the 97th Annual Meeting of the Endocrine Society (ENDO) on March 6th, 2015 in San Diego, California, that will include twelve months data from OPKO's phase 3 trials for Rayaldee™ as a treatment for secondary hyperparathyroidism (SHPT) in patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency. The data to be presented include results for 429 patients completing up to twelve months of treatment.
OTTAWA, Ontario--(BUSINESS WIRE)--Nakina announced today that Turk Telekom, the leading national operator providing fixed and mobile voice, video and data services to consumer and commercial customers throughout Turkey, is
OTTAWA, Ontario--(BUSINESS WIRE)--Nakina announced today it is joining in the Intel® Network Builders program-- a program designed to accelerate deployment of software-defined networking (SDN) and network function virtu
Expansion plans at GreenField Specialty Alcohols Inc. in Chatham are taking shape.The company announced $40-million worth of investments in capital projects at the plant on Bloomfield Road in October.Angelo Ligori, plant manger, gave an update on the plans during a presentation at the Chatham-Kent Farm Show Wednesday.“Most people still think we’re a fuel (ethanol) plant,” said Ligori of the company’s future plans. “That’s ‘old-school.’ We’ve moved on.